Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile

Table 3

Haplotype frequencies and comparison between Crohn’s patients, responders and nonresponders to infliximab therapy, in the chromosomal regions including (a) S100A9 and S100A8 genes (rs11205276, rs3014866, rs724781, and rs3006488); (b) G0S2 gene (rs4844486, rs1473683); (c) TNFAIP6 gene (rs11677200, rs2342910, rs3755480, and rs10432475); and (d) IL11 gene (rs1126760, rs1042506).

(a)

Haplotype	Responders (%)	Nonresponders (%)	value
GCCA	22.8	31.4	0.05
GTCA	24.6	18.4	0.16
GCGA	21.5	19.7	0.63
CTCA	9.3	10.9	0.57
GTGA	4.9	1.9	0.11
CCCA	4.1	3.4	0.73
GCCG	3.8	4.4	0.77
GTGG	2.4	4.4	0.28
CCGA	2.1	1.8	0.77
GCGG	1.5	1.7	0.92
GTCG	1.3	1.0	0.72
CTGA	1.1	0.7	0.83

(b)

Haplotype	Responders (%)	Nonresponders (%)	value
CG	72.4	74.3	0.61
AG	26.3	23.0	0.43
AT	0.8	2.4	0.12

(c)

Haplotype	Responders (%)	Nonresponders (%)	value
CAGA	43.0	34.8	0.10
TAGA	17.4	21.6	0.24
TTGA	16.8	15.3	0.68
TAAA	12.3	16.1	0.24
TTGG	10.2	12.1	0.60

(d)

Haplotype	Responders (%)	Nonresponders (%)	value
TT	76.5	72.2	0.38
CG	12.8	10.0	0.50
CT	10.0	15.7	0.07
TG	0.7	2.0	0.25